Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)

Do You Have These Pharma Stocks In Your Portfolio? (EARS, BLRX, OMED…)
Clinical trials are major catalysts for biotech/pharma companies as positive study data can boost the stock price while unfavorable results can send the stocks plummeting. The success rate of phase I clinical programs is the highest, say 63%, while it is the lowest for phase II trials – i.e. 30%. The phase III trials, which are the longest and most... Read More

SNGX Flashes DMC Recommendation, LENS On Watch, IOVA Slumps

SNGX Flashes DMC Recommendation, LENS On Watch, IOVA Slumps
The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Soligenix Inc. (SNGX) Lost 26.21% to close Monday’s (Oct.15) trading at $1.07. News: An independent Data Monitoring Committee has recommended that approximately 40 additional subjects be randomized into the Company’s phase III study for SGX301 in the treatment of cutaneous T-cell lymphoma, dubbed FLASH.... Read More

Krystal Bio Shines, CGC Hits Lifetime High, ANIX On Watch, CRON Gathers Steam

Krystal Bio Shines, CGC Hits Lifetime High, ANIX On Watch, CRON Gathers Steam
The following are some of today’s top gainers in the pharma/biotech sector. 1. Krystal Biotech Inc. (KRYS) Gained 27.55% to close Monday’s (Oct.15) trading at $20.00. News: The Company announced positive interim results from its ongoing placebo-controlled phase I/II clinical trial of KB103 to treat dystrophic epidermolysis bullosa, or DEB. DEB is an incurable, often fatal skin blistering condition caused... Read More

Stocks Fluctuate Before Closing Mostly Lower – U.S. Commentary

Stocks Fluctuate Before Closing Mostly Lower – U.S. Commentary
Stocks fluctuated over the course of the trading session on Monday following the rebound seen last Friday. After recovering from an early move to the downside, the major averages spent the day bouncing back and forth across the unchanged line. The major averages ended the day firmly in negative territory. The Dow fell 89.44 points or 0.4 percent to 25,250.55,... Read More

Stocks Regain Ground After Early Move To The Downside – U.S. Commentary

Stocks Regain Ground After Early Move To The Downside – U.S. Commentary
After an early move to the downside, stocks have regained ground over the course of the trading session on Monday. The major averages have climbed well off their worst levels of the day. Currently, the major averages are turning in a mixed performance. While the Dow is up 5.89 points or less than a tenth of a percent at 25,345.88,... Read More

Stocks Move Mostly Lower In Morning Trading – U.S. Commentary

Stocks Move Mostly Lower In Morning Trading – U.S. Commentary
Stocks have moved mostly lower in morning trading on Monday, partly offsetting the rebound seen last Friday. The major averages have all moved to the downside, although selling pressure has remained somewhat subdued. Currently, the major averages are all in negative territory, although the Dow is down just 22.39 points or 0.1 percent at 25,317.60. The Nasdaq is down 72.83... Read More

Week Ahead In Pharmaceuticals: 6 Stocks To Watch (BPMC, BHC, ACRX…)

Week Ahead In Pharmaceuticals: 6 Stocks To Watch (BPMC, BHC, ACRX…)
Another week has rolled by, and the biotech sector, being a volatile one, saw some stocks soaring to the moon and some hitting the skids. vTv Therapeutics Inc. (VTVT) closed the week, up 238%, at $3.35. The Company’s most advanced drug candidate is Azeliragon, which failed in a phase III trial in patients with mild Alzheimer’s disease, dubbed STEADFAST. Vaxart... Read More

Stocks Close Firmly Negative Amid Interest Rate Worries – U.S. Commentary

Stocks Close Firmly Negative Amid Interest Rate Worries – U.S. Commentary
Stocks saw considerable weakness during the trading session on Thursday, extending the pullback seen in afternoon trading on Wednesday. With the drop on the day, the Dow gave back ground after ending yesterday’s trading at a record closing high. The major averages climbed well off their worst levels of the session but still finished the day firmly in the red.... Read More